Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Long Covid
ISRCTN46454974Phase 2Completed
- Sponsor
- University of Leicester
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Health-related quality of life. Started Feb 2024; status: completed.
02
Drugs
tocilizumab
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on ISRCTN46454974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN46454974.